Pulmonary fibrosis (PF) is a chronic disease in which healthy lung tissue is progressively replaced by fibrous tissue, which impairs respiratory function. Its prognosis is often poor, and currently, the only treatment that can extend both quality and length of life is lung transplantation, an option limited by multiple restrictions.
Stem cells, thanks to their powerful regenerative, antifibrotic, anti-inflammatory, and immune-modulating properties, have demonstrated a robust safety, tolerability and benefit profile in animal models with PF.
In this context, the authors of this article have compiled findings from various studies on the use of stem cells for treating PF patients. They analyzed 13 studies published between 2013 and 2021, which included a total of 198 patients with an average follow-up of approximately one year.
According to the review, “the results demonstrate that stem cell therapy provides varying levels of improvement in patients with mild to moderate PF, as well as in those with a rapidly progressive form in moderate to severe stage. Notably, none of the studies reported serious or clinically relevant adverse events.”
The researchers conclude that “despite the challenges yet to be overcome, technological advances and ongoing research offer a promising perspective for stem cells as a key tool in the fight against PF.”
Reference: Wan R, Liu Y, Yan J, Lin J. Cell therapy: A beacon of hope in the battle against pulmonary fibrosis. FASEB J. 2025 Jan 31;39(2):e70356. doi: 10.1096/fj.202402790R.
